Select a Contributor Response

Conversations:

See What Industry Leaders, Legislators, Experts and PhRMA Members are Discussing Now at PhRMA’s Annual Meeting. Join the Conversation Using #PhRMA14

View All Conversations

 

See What Industry Leaders, Legislators, Experts and PhRMA Members are Discussing Now at PhRMA’s Annual Meeting. Join the Conversation Using #PhRMA14

Test Name
Test Title, Test Company

Read biography×

See What Industry Leaders, Legislators, Experts and PhRMA Members are Discussing Now at PhRMA’s Annual Meeting. Join the Conversation Using #PhRMA14

Amy Comstock Rick
CEO, Parkinson’s Action Network

Read biography×

Amy Comstock Rick
CEO, Parkinson’s Action Network

Follow Amy on:

Amy Comstock Rick is CEO of Parkinson’s Action Network (PAN). PAN’s national advocacy network educates the public and lawmakers about the effects of Parkinson's disease and the need for federal research funding and policy support for the 500,000 – 1.5 million Americans living with the disease.

Rick has testified before several congressional committees and subcommittees and in 2011 was honored as an Innovator by the Genetic Alliance for her work on federal embryonic stem cell research policy.

As CEO of PAN, Ms. Rick currently serves as an officer or board member with several national coalitions and councils. She serves on the National Neurological Disorders and Stroke Advisory Council, the principal advisory body to the National Institute of Neurological Disorders and Stroke (NINDS) at NIH. She serves as Treasurer for the American Brain Coalition (ABC), a national non-profit organization comprised of some of the United States’ leading professional neurological, psychological, and psychiatric associations and patient organizations that, together, seek to advance the understanding of the functions of the brain, and to reduce the burden of brain disorders through public advocacy. She serves on the Board of Directors for the National Health Council, a national non-profit that brings together all segments of the health community to provide a united voice for the more than 133 million people with chronic diseases and disabilities and their family caregivers. Ms. Rick also sits on the Board of Directors for Research!America, the nation's largest not-for-profit public education and advocacy alliance committed to making research to improve health a higher national priority. She also served as president and board member for the Coalition for the Advancement of Medical Research, a national leading bipartisan pro-cures coalition comprised of 100 nationally recognized patient organizations, universities, scientific societies, and foundations that successfully accomplished its mission and dissolved in early 2013.

Prior to joining PAN, Amy was the U.S. Senate-confirmed Director of the U.S. Office of Government Ethics from 2000-2003, and Associate Counsel to the President in the White House Counsel’s Office from 1998-2000. She began her federal service in 1988 as an attorney at the U.S. Department of Education, and left in 1998 as Assistant General Counsel for Ethics. She received a Bachelor of Arts degree from Bard College and a Juris Doctor degree from the University of Michigan.

×

See What Industry Leaders, Legislators, Experts and PhRMA Members are Discussing Now at PhRMA’s Annual Meeting. Join the Conversation Using #PhRMA14

Sally Greenberg
Executive Director, National Consumers League

Read biography×

Sally Greenberg
Executive Director, National Consumers League

Follow Sally on:

Sally Greenberg joined the National Consumers League as Executive Director on October 1, 2007. The League’s focus is on five key priority areas: fraud, child labor, LifeSmarts, health care, especially the safe use of medications and medication adherence, and food safety and nutrition. Sally has testified numerous times before Congress on consumer protection issues, including on product safety, fraud, excessive fees on car rentals, consumer rip-offs in calling cards and in support of protections for farmworker children. Sally is our primary spokesperson on a variety of issues.

Sally came to NCL from Consumers Union, where she worked from 1997-2007 on product liability and food safety issues, along with auto and product safety. Previously, Sally worked at the U.S. Department of Justice Foreign Claims Settlement Commission and prior to that, she spent a decade serving as the Eastern States Civil Rights Counsel for the Anti-Defamation League, based in Boston.

Sally was president of the Women’s Bar Association of Massachusetts and the Women’s Bar Foundation, and served on several gubernatorial commissions in Massachusetts. Currently Sally continues to serve on the board of directors of the Alliance for Justice, and HALT, an organization whose mission is the protection of the rights of consumers in their interactions with lawyers and the legal system. Sally recently joined the Reagan-Udall Foundation Board, a nonprofit established by Congress to support the mission of the FDA and help equip the agency with the highest caliber regulatory science and technology. She also serves on the board of the Keystone Center, which helps leaders in health, energy, environment and education battle contentious issues with a consensus-based approach. Sally also served for over a decade on the board of directors of Trillium Asset Management, the oldest and largest investment management firm dedicated to socially responsible investing.

×

See What Industry Leaders, Legislators, Experts and PhRMA Members are Discussing Now at PhRMA’s Annual Meeting. Join the Conversation Using #PhRMA14

Sharon F. Terry
President and CEO , Genetic Alliance

Read biography×

Sharon F. Terry
President and CEO , Genetic Alliance

Follow Sharon on:

Sharon F. Terry is President and CEO of Genetic Alliance, a network of more than 10,000 organizations, of which 1,200 are disease advocacy organizations. Genetic Alliance enables individuals, families, and communities to reclaim their health and become full participants in translational research and services.

She is the founding CEO of PXE International, a research advocacy organization for the genetic condition pseudoxanthoma elasticum (PXE). As co-discoverer of the gene associated with PXE, she holds the patent for ABCC6 to act as its steward and has assigned her rights to the foundation. She developed a diagnostic test and conducts clinical trials. She is the author of 120 peer-reviewed papers, of which 30 are PXE clinical studies.

Sharon is also a co-founder of the Genetic Alliance Registry and Biobank. In her focus at the forefront of consumer participation in genetics research, services, and policy, she serves in a leadership role on many of the major international and national organizations, including the Institute of Medicine (IOM) Science and Policy Board, the IOM Roundtable on Translating Genomic-Based Research for Health, the PubMed Central National Advisory Committee, the International Rare Disease Research Consortium Executive Committee, PhenX, Global Alliance, and as Founding President of EspeRare Foundation. She is on the editorial boards of several journals. She was instrumental in the passage of the Genetic Information Nondiscrimination Act. She received an honorary doctorate from Iona College for her work in community engagement in 2005; the first Patient Service Award from the UNC Institute for Pharmacogenomics and Individualized Therapy in 2007; the Research!America Distinguished Organization Advocacy Award in 2009; and the Clinical Research Forum and Foundation’s Annual Award for Leadership in Public Advocacy in 2011. In 2012, she became an honorary professor of Hebei United University in Tangshan, China, and received the Facing Our Risk of Cancer Empowered (FORCE) Spirit of Empowerment Advocacy Award. She was named one of FDA’s “30 Heroes for the Thirtieth Anniversary of the Orphan Drug Act” in 2013. She is an Ashoka Fellow.

She has received three first place prizes in competitions for the Platform for Engaging Everyone Responsibly (PEER) totaling more than $350,000. PEER was named one of "Six Business Models that are Transforming Health Systems around the World" in 2013.

×

See What Industry Leaders, Legislators, Experts and PhRMA Members are Discussing Now at PhRMA’s Annual Meeting. Join the Conversation Using #PhRMA14

Wendy K.D. Selig
President and CEO, Melanoma Research Alliance

Read biography×

Wendy K.D. Selig
President and CEO, Melanoma Research Alliance

Follow Wendy on:

Wendy K.D. Selig is President and CEO of the Melanoma Research Alliance (MRA), a public charity focused on finding and funding the most promising melanoma research worldwide to accelerate progress toward a cure.   Ms. Selig drives and manages MRA’s strategic priorities, research portfolio, and day‐to‐day operations. Under her leadership, MRA is accelerating progress toward a cure for melanoma by supporting an international, cross‐disciplinary group of biomedical researchers exploring, identifying, and pursuing innovative, transformative research.  

Prior to joining the MRA, Ms. Selig spent nearly a decade in leadership positions at the American Cancer Society and its advocacy affiliate, the American Cancer Society Cancer Action Network (ACS CAN). She currently chairs the Board of Directors of the National Coalition of Cancer Research (NCCR), and is a member of the Government Affairs Committee of the

Prostate Cancer Foundation (PCF), and the Patient Leadership Council (PLC) of the Clinical Trials Transformation Initiative (CTTI).  She previously served as Chair of the United for Medical research (UMR) coalition and a member of the Directors Consumer Liaison Group (DCLG) at the National Cancer Institute (NCI).  From 1989‐2000, Ms. Selig served on Capitol Hill as a top aide for U.S. Representative Porter J. Goss (R‐FL), the House Rules Committee and the House Permanent Select Committee on Intelligence (HPSCI).  Ms. Selig is a Magna Cum Laude graduate of Princeton University and holds a Masters in Science from Northwestern University’s Medill School of Journalism.

×

See What Industry Leaders, Legislators, Experts and PhRMA Members are Discussing Now at PhRMA’s Annual Meeting. Join the Conversation Using #PhRMA14

Millicent Gorham
#PhRMA14 Attendee, Nat. Black Nurses Assoc.

Read biography×

Millicent Gorham
#PhRMA14 Attendee, Nat. Black Nurses Assoc.

Millicent Gorham attended #PhRMA14 and contributed to the conversation around Wednesday's meeting.

×

See What Industry Leaders, Legislators, Experts and PhRMA Members are Discussing Now at PhRMA’s Annual Meeting. Join the Conversation Using #PhRMA14

Andrew Sperling
#PhRMA14 Attendee, NAMI

Read biography×

Andrew Sperling
#PhRMA14 Attendee, NAMI

Andrew Sperling attended #PhRMA14 and contributed to the conversation around Wednesday's meeting. Mr Sperling is the Director of Federal Legislative Advocacy for NAMI, the National Alliance on Mental Illness. 

×

See What Industry Leaders, Legislators, Experts and PhRMA Members are Discussing Now at PhRMA’s Annual Meeting. Join the Conversation Using #PhRMA14

Carl Schmid
Deputy Executive Director, The AIDS Institute

Read biography×

Carl Schmid
Deputy Executive Director, The AIDS Institute

Follow Carl on:

Carl Schmid was named Deputy Executive Director of The AIDS Institute, a national public policy, advocacy and research organization, in June, 2009. Prior to that he served as the Institute’s Director of Federal Affairs, a position he held since February 2004. Prior to joining The AIDS Institute, he served as a consultant to a number of HIV/AIDS and civil rights organizations. He has worked in Washington for over 20 years, and began his public policy work in the energy arena, which continued through 2003. 

Mr. Schmid is co‐chair of the AIDS Budget and Appropriations Coalition; a Convening Group member of the Federal AIDS Policy Partnership, and co‐chair of an HIV Testing Reimbursement Work Group. He is a former chair of the HIV Prevention Action Coalition and the Ryan White Reauthorization Work Group. He remains active in those coalitions along with others that advocate for Medicaid, Medicare, and Healthcare Reform; the AIDS Drug Assistance Program (ADAP), and Hepatitis issues. 

He was a member of the Presidential Advisory Council on HIV/AIDS from 2007 to 2009, and Chaired its Domestic Subcommittee. In 2010 he was named by POZ Magazine as one of the 100 most effective AIDS fighters in the nation and was recently named by Whitman Walker Health as one of the 25 individuals who have played prominent roles in the fight against HIV/AIDS in DC over the past 25 years. 

Mr. Schmid earned a B.A. in Public Affairs and a M.B.A. in International Affairs from the George Washington University in Washington, D.C.

 

×

See What Industry Leaders, Legislators, Experts and PhRMA Members are Discussing Now at PhRMA’s Annual Meeting. Join the Conversation Using #PhRMA14

Scott Smith
#PhRMA14 Attendee, GlaxoSmithKline

Read biography×

Scott Smith
#PhRMA14 Attendee, GlaxoSmithKline

Scott Smith attended #PhRMA14 and contributed to the conversation around Thursday's meeting. 

×

See What Industry Leaders, Legislators, Experts and PhRMA Members are Discussing Now at PhRMA’s Annual Meeting. Join the Conversation Using #PhRMA14

Christopher W. Hansen
President, ACS CAN

Read biography×

Christopher W. Hansen
President, ACS CAN


Christopher W. Hansen is the President of the American Cancer Society Cancer Action Network (ACS CAN), the nonprofit, nonpartisan advocacy affiliate of the American Cancer Society. As President, Hansen leads an organization of more than 100 staff in Washington, D.C. and across the country in support of laws and policies that help people fight cancer and advance the Society’s mission to save lives from cancer and create more birthdays. He was named to the position in June 2010.

Hansen is a seasoned nonprofit and corporate leader with more than 36 years of Washington experience. He joined ACS CAN in June 2010 after serving as the President and Chief Executive Officer of the American Electronic Association at a pivotal time for the organization, leading its successful transformation in a 2009 merger with several other technology groups to form Tech America, the nation’s largest association representing all segments of the high-tech industry. Hansen served as the new organization’s Chief Executive Officer before becoming CEO Emeritus and President of the association’s 501(c)(3) affiliate, TechAmerica Foundation.

Prior to his tenure in the technology field, Hansen served in senior leadership positions at AARP from 2002 to 2007, most recently as Group Executive Officer, State and National Initiatives. In that role he directed all federal, state, and grassroots advocacy initiatives nationwide and managed more than 50 AARP offices and 750 staff in Washington, D.C. and across the nation. He began his career at AARP as Senior Managing Director, Government Relations and Advocacy and directed all federal, state, grassroots, and legal advocacy on behalf of the organization’s 35 million members.

Hansen also has more than 15 years of experience with the Boeing Company, where he led all federal, state, and international government relations and served as a corporate officer and executive council member. His earlier experience includes roles in the congressional affairs group at General Dynamics.

Hansen holds an undergraduate degree in political science from the University of Denver and a master’s from the American Graduate School of International Management. He has held a number of leadership roles in professional organizations, including the U.S. Council for International Business, the National Aeronautics Association, the National Bureau of Asian Research, and the Individual Investors Committee of the New York Stock Exchange. He is also active in philanthropic organizations such as the Wolf Trap Foundation.

Read Chris Hansen's Conversations Responses

×

See What Industry Leaders, Legislators, Experts and PhRMA Members are Discussing Now at PhRMA’s Annual Meeting. Join the Conversation Using #PhRMA14

Randall L. Rutta
Chief Strategy Officer, Executive Vice President, Easter Seals

Read biography×

Randall L. Rutta
Chief Strategy Officer, Executive Vice President, Easter Seals

Follow Randall on:


Randall Rutta is Chief Strategy Officer and Executive Vice President for Public Affairs for Easter Seals’ corporate headquarters.  As CSO, he collaborates with Easter Seals’ CEO and other executives to advance creation, execution, and assessment of strategic initiatives at all levels of the organization.

He manages the Office of Public Affairs, which is located in Washington, DC. He also manages Easter Seals’ Business Innovation and Growth Department and Program Services Department, which together support service innovation and mission-based impact growth at Easter Seals through research-to-practice collaboration, professional training, technical assistance, and information dissemination in all major areas of life activity affecting people with autism and other disabilities, age-related impairments and chronic conditions.

Mr. Rutta oversees several federally-funded projects conducted by Easter Seals to provide training, technical assistance, and information dissemination activities, including Project ACTION and the National Center on Senior Transportation that promote access to transportation for people with disabilities and older adults with mobility needs, and the Senior Community Service Employment Program that provides training and promotes employment for older disadvantaged workers

Mr. Rutta serves on the Board of Directors of the U.S. International Council on Disability, which represents the U.S. disability community in international issues and activities. He serves on the Board of Directors of the Partnership to Fight Chronic Disease and represents Easter Seals in PFCD efforts promoting increased attention to the prevention and management of chronic disease in America’s health care system, serves on the Steering Committee of Prescriptions for a Healthy America, and serves on the Patient Advocacy Committee of the National Association of Chain Drug Stores.

Mr. Rutta has been with Easter Seals since 1981.  He holds a Bachelors of Arts degree in Sociology and a Masters of Arts degree in Politics, focusing on international health policy.  His career experience has been in acute care, health care quality assurance, and health policy development and implementation.

For information contact Randall Rutta at (202) 347-3066 or via e-mail: rrutta@easterseals.com.  

×

See What Industry Leaders, Legislators, Experts and PhRMA Members are Discussing Now at PhRMA’s Annual Meeting. Join the Conversation Using #PhRMA14

Danielle Pere
#PhRMA14 Attendee, ACPM

Read biography×

Danielle Pere
#PhRMA14 Attendee, ACPM

Follow Danielle on:

Danielle attended #PhRMA14 in Washington DC, April 9-11, 2014. 

×

See What Industry Leaders, Legislators, Experts and PhRMA Members are Discussing Now at PhRMA’s Annual Meeting. Join the Conversation Using #PhRMA14

David Miller
President and CEO , iBIO

Read biography×

David Miller
President and CEO , iBIO

David E. Miller is president and CEO of the Illinois Biotechnology Industry Organization (iBIO), a life sciences trade organization that comprises leaders from the private, public and educational sectors. In this position, he also serves as the president and CEO of the iBIO Institute, which orchestrates business leadership in delivery of world-class educational programs and job-creating new technology ventures.

Prior to joining iBIO, David served in executive positions for technology start-ups: Vice President of Corporate Development for AppsPoint Corporation in Silicon Valley; Vice President of Business Development and Vice President of Sales & Marketing for Clear Communications in Chicago; and President of Joiner Associates, in Madison, Wisconsin.

Before that, David served as business aide for the Mayor of Madison, Wisconsin, where he initiated a world-first, quality-productivity effort based on Deming/Japanese practices; he also drove the city’s efforts to establish the heralded University of Wisconsin Research Park. David served as Managing Partner of New Age Housing, a developer of solar housing, and as a General Partner of Wyndemere Partners, a developer of energy-efficient conventional housing, both in Wisconsin.

David also initiated successful projects for divisions of Fortune 500 companies: as Regional Counsel for the Hartford Insurance Group subsidiary of ITT, and as Real Estate Attorney for the Richman Brothers division of Woolworth Corporation. David earned his B.A. from Tufts University and his J.D. from Case Western Reserve School of Law.

×

See What Industry Leaders, Legislators, Experts and PhRMA Members are Discussing Now at PhRMA’s Annual Meeting. Join the Conversation Using #PhRMA14

Jeffrey M. Gallagher
CEO, Virginia Bio

Read biography×

Jeffrey M. Gallagher
CEO, Virginia Bio

Follow Jeffrey on:

Jeffrey M. Gallagher, CEO of Virginia Bio, is responsible for leading the premier statewide trade group that promotes the considerable scientific and economic impact of the life sciences industry in the Commonwealth of Virginia. Prior to taking on the leadership of Virginia Bio in May 2012, Jeff was a co-founder and served as VP & General Counsel for Lyotropic Therapeutics. This small specialty pharma company used its proprietary formulation technology to create new drug products based on both NCIs and already approved API for license, further development and commercialization by mid and large pharma. Previously he practiced corporate law in Richmond, focusing on new technology company formation, international business and intellectual property transactions. He was a co-founder and longtime Chairman of the Richmond based nonprofit World Pediatric Project. He holds an A.B. in Government from Harvard, a J.D. from the University of Wisconsin Law School, and an LL.M in Public International Law from the University of Virginia School of Law. He resides with his family in the Ginter Park area of Richmond, VA.

×
This is a test modal